TRPM2 and non-small cell lung carcinoma: These in vitro and in vivo results clearly demonstrate that blockade of TRPM2 downregulation attenuates the ability of osimertinib to decrease survival and induce apoptosis of EGFRm NSCLC cells and inhibit the growth of EGFRm NSCLC tumors, implying an essential role of TRPM2 downregulation in mediating the therapeutic efficacy of osimertinib against EGFRm NSCLC cells.